PRLD logo

PRELUDE THERAPEUTICS INC

PRLDNASDAQ
🏆 #3458 by market capEarnings Nov 10US Equity
——
Quote unavailable
🔔
Track PRLD
Get earnings, price moves & breaking news on Telegram
Track
24h—
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$240M
Small Cap
📈Revenue Growth (YoY)
73.4%
High Growth
📊Gross Margin
98.3%
High
💵FCF Margin
-148.3%
Thin
⚖️P/S Ratio
10.7x
Elevated
Otter Score
—
Insufficient data
No chart data available for PRLD.

Trading Snapshot

Day Range
—
52-Week Range
$1.17 – $6.83
Volume (shares)
—
Avg Volume (shares)
—
Shares Outstanding
57.9M
Next Earnings
2026-11-10

Fundamentals Snapshot

Annual Revenue
$12M
Last Q Revenue
$6M
P/E Ratio
-5.2
P/S Ratio
10.7x
EPS (TTM)
$-0.61
Dividend Yield
0.00%
Dilution (1yr)
−17.1%
PRLD logo

PRELUDE THERAPEUTICS INC

PRLD
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$12M▲ +73.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
85.9%▼ −14.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$105M▼ −25.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$56M▼ −45.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
63.0M▼ −17.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$17M▲ +$23M YoY
StockOtter · stockotter.space

About PRELUDE THERAPEUTICS INC

Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.